Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

High materiality8/10

Entera Bio Advances EB613 with FDA Alignment and $275M Financing

Aug 7, 2026, 4:09 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Key near-term catalysts (FDA alignment, sizable financing, and Phase 3 timing) could lift valuation; dilution risk from a large PIPE exists but is offset by extended runway and clearer development path.

AI summary

What happened, with direct paths to the underlying reporting

Entera Bio announced FDA alignment for EB613's 12-month registrational Phase 3 in about 750 postmenopausal women, with topline data expected in 2H2028. The July 2026 private placement of $275M strengthens cash runway into 2030 and supports EB613, EB612, and related programs. Additional updates include EB612 IND planning for H1 2027 and EB618 preclinical progress, reinforcing near-term value and execution risk management.

FDA aligned EB613 Phase 3 plan for osteoporosis; topline 2H2028.
Oversubscribed $275M private placement funds EB613 NDA and timeline.
EB613 single-tablet data presented at ENDO 2026 supports Phase 3.
EB612 IND targeted for H1 2027 via OPKO collaboration expansion.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Entera Bio Advances EB613 with FDA Alignment and $275M Financing

Entera Bio secures financing to extend runway and advance EB613 toward FDA

Entera Bio Posts Losses, Suffering Significant Share Price Drop